You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
SBC: GLYTR THERAPEUTICS, INC. Topic: 102AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Water-based liquid embolic agent for the treatment of vascular rich tumors
SBC: AQUATEX MEDICAL INC Topic: 102AquaTeX Medical is developing a novel liquid embolic material (LEM) - Aqua Embolic System (AES) - to improve cancer treatment. AES is designed to occlude feeding vessels of hypervascular tumors with superior efficacy and excellent biocompatibility as compared to other trans-arterial embolization (TAE) materials.TAE is a catheter-based treatment to treat hypervascular tumors. Embolic materials are ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
SBC: TRIANGLE THERAPEUTICS INC. Topic: 300PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one million Americans and is a type of inflammatory bowel disease. CD is driven by CD4 T cells with a significant role for TH1 and TH17 cells and additional involvement of B cells. Current therapies for CD ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity
SBC: TURTLETREE LABS INC. Topic: NICHDProject Summary/Abstract Most infants currently rely on infant formula (IF) to meet their nutritional needs. However, existing infant formula is functionally inferior because it lacks breast milk bioactive proteins that are crucial to infant health and development. Consequently, formula-fed infants have increased risk of morbidity and mortality. Current technology limits the ability to add bioacti ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT The goal of the proposed project is to evaluate the clinical potential of HBI-002, a novel oral low dose carbon monoxide (CO) drug product, that enables the use of low dose CO to prevent Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease (SCD). Numerous studies, both preclinical and clinical, demonstrate that CO has dual mechanisms of action including anti-sickling and an ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Multi-Platform Homogeneous Multiplexed Autoantibody Assay Based on Liquid Micropiston-Enhanced Time-Resolved Forster Resonance Energy Transfer
SBC: WAVE 80 BIOSCIENCES, INC. Topic: 200Project Summary Detection and quantitation of autoantibodies is increasingly prioritized for diagnosis and management of type 1 diabetes (T1D). Assay methods and systems that can achieve clinically relevant performance in detecting and quantitating T1D-relevant autoantibodies—from the standpoint of key performance parameters such as sensitivity, specificity, reproducibility, and quantitative acc ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Genetic adjuvants to elicit neutralizing antibodies against HIV
SBC: TENDEL THERAPIES INC Topic: 105This project will test the ability of T follicular helper (Tfh) cell-targeting “genetic adjuvants” to improve immunogenicity of an advanced HIV envelope (Env) trimer. Eliciting neutralizing antibodies (nAb) against HIV will likely be required to create effective therapeutic vaccines that attenuate HIV disease progression, reduce HIV infectiousness, or even effect sustained remission in the abs ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
The Neurospan Bridge: A Device for Peripheral Nerve Repair
SBC: AUXILIUM BIOTECHNOLOGIES INC. Topic: NINDSPeripheral Nerve Injury (PNI) occurs in 3% of all trauma cases and 30% of combat injuries to the extremities, resulting in a loss of five million working days each year and costs of $150 billion annually in the U.S. The standard of care in the clinic is a nerve autograft from the patients’ leg. The NeuroSpan Bridge is a unique, biomimetic, multi-channel scaffold that maintains linearity througho ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury
SBC: Silicon Kidney Topic: 400Project Summary Acute Kidney Injury (AKI) commonly occurs in critically ill patients in the ICU. Patients with severe AKI often require continuous renal replacement therapy (CRRT) because it enables hemodynamic stability and better volume control. Anticoagulation therapy is frequently used to keep the CRRT circuit (especially the blood filter) from clotting as many critically ill patients are prot ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health